FDA says ProHealth marketed St. John's Wort Extract as an unapproved drug for depression and anxiety.
What happened
FDA reviewed www.prohealth.com in December 2020 and found that ProHealth takes orders there for Full Spectrum™ St. John's Wort Extract. The website said the product is "Effective for mild to moderate depression" and "Reduces anxiety." FDA said those claims make it a drug, an unapproved new drug, and misbranded because it lacks adequate directions for use.
What FDA found
The website claims the product treats mild to moderate depression and reduces anxiety, which makes it a drug intended to treat disease.
Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]The product is a new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.
Section 201(p) of the Act [21 U.S.C. § 321(p)]The product is introduced or delivered for introduction into interstate commerce without the required FDA approval.
Sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]The product is misbranded because it lacks adequate directions for use; depression and anxiety are not suitable for self-treatment without a licensed practitioner.
Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5Introducing or delivering the misbranded product into interstate commerce violates the Act.
Section 301(a) of the Act [21 U.S.C. § 331(a)]
What FDA wants
FDA tells ProHealth to take prompt action to correct the violations and to notify FDA in writing within 15 working days of the steps taken, including how it will prevent recurrence. If it cannot finish in that time, it must explain the delay and give a completion date.
Who should pay attention
- supplement brands that make disease-treatment claims
- e-commerce sellers of herbal products
- labeling and regulatory reviewers for dietary supplement companies
This is a summary. Read the original letter on fda.gov.